Details
Stereochemistry | ACHIRAL |
Molecular Formula | C3H9O6P |
Molecular Weight | 172.0737 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC(CO)OP(O)(O)=O
InChI
InChIKey=DHCLVCXQIBBOPH-UHFFFAOYSA-N
InChI=1S/C3H9O6P/c4-1-3(2-5)9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)
DescriptionSources: https://www.drugs.com/ppa/sodium-glycerophosphate-pentahydrate.html | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | http://www.medsafe.govt.nz/profs/Datasheet/g/Glycophosinf.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/573222 | https://www.ncbi.nlm.nih.gov/pubmed/22961670 | https://www.ncbi.nlm.nih.gov/pubmed/15265286https://www.ncbi.nlm.nih.gov/pubmed/19275097 | https://www.ncbi.nlm.nih.gov/pubmed/929612 | https://www.ncbi.nlm.nih.gov/pubmed/4140270 | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | https://www.ncbi.nlm.nih.gov/pubmed/22383088
Sources: https://www.drugs.com/ppa/sodium-glycerophosphate-pentahydrate.html | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | http://www.medsafe.govt.nz/profs/Datasheet/g/Glycophosinf.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/573222 | https://www.ncbi.nlm.nih.gov/pubmed/22961670 | https://www.ncbi.nlm.nih.gov/pubmed/15265286https://www.ncbi.nlm.nih.gov/pubmed/19275097 | https://www.ncbi.nlm.nih.gov/pubmed/929612 | https://www.ncbi.nlm.nih.gov/pubmed/4140270 | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | https://www.ncbi.nlm.nih.gov/pubmed/22383088
Sodium glycerol 2-phosphate (Disodium beta-glycerophosphate) is used for the preparation of thermo-sensitive chitosan hydrogen as a scaffold to construct tissue engineered injectable nucleus pulposus (NP). Since Sodium glycerol 2-phosphate (6 g/day) reduced the lithogenic index of
bile in human subjects with cholesterol gallstones in a short-term study
and facilitated dissolution of cholesterol gallstones in mice, Sodium glycerol 2-phosphate may have potential to help dissolve cholesterol gallstones
in man. Sodium glycerol 2-phosphate is an alkaline phosphate inhibitor. Sodium β-glycerophosphate pentahydrate is used as a phosphatase inhibitor. It promotes bone matrix mineralization while delivering to osteoblasts by providing a source of phosphate ions. It is used in the development of hydrogels and scaffolds, which finds applications in tissue engineering and cell growth. It is used as an additive in isolation mediums by providing phosphate ions to isolate. It is utilized to promote mineralization in vitro by modulating bone cell metabolic activity.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5979 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22383088 |
|||
Target ID: Protein phosphatase |
|||
Target ID: Glycerol-2-phosphatase |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1060200 |
Primary | Unknown Approved UseUnknown |
||
Primary | Glycophos Approved UseGlycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate. |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of oral administration of 'essential' phospholipid, beta-glycerophosphate, and linoleic acid on biliary lipids in patients with cholelithiasis. | 1979 |
|
Pericytes derived from the retinal microvasculature undergo calcification in vitro. | 1990 Nov |
|
Mechanism of action of beta-glycerophosphate on bone cell mineralization. | 1992 Oct |
|
Enhancing effect of daidzein on the differentiation and mineralization in mouse osteoblast-like MC3T3-E1 cells. | 2006 Aug |
|
Antibacterial properties of Ag (or Pt)-containing calcium phosphate coatings formed by micro-arc oxidation. | 2009 Jan |
|
[Comparison study on injectable tissue engineered nucleus pulposus constructed by different cells and chitosan hydrogel]. | 2010 Jul |
|
Taurine suppresses osteoblastic differentiation of aortic valve interstitial cells induced by beta-glycerophosphate disodium, dexamethasone and ascorbic acid via the ERK pathway. | 2012 Oct |
|
Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis. | 2018 Aug |
Sample Use Guides
Dose
Adults:
The recommended dosage is individual. The recommended daily dosage of
phosphate during intravenous nutrition would normally be 10-20 mmol. This can be
met by using 10-20 mL of GLYCOPHOS (Sodium glycerophosphate pentahydrate) added to the infusion solution or to the
admixture for which compatibility has been proved.
Children, Infants and Neonates:
The recommended dosage is individual. The recommended dose for children,
infants and neonates is 1.0-1.5 mmol/kg body weight/day.
Method of administration
Intravenous Infusion.
GLYCOPHOS must not be given undiluted. The infusion time should not be less than 8 hours.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1422975
Medium supplementation with beta-GP (Sodium 2-glycerophosphate) should not exceed 2 mM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID1023106
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY | |||
|
241-228-2
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY | |||
|
WWH06G87W6
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY | |||
|
2526
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY | |||
|
m5792
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB01779
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY | |||
|
17270
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY | |||
|
C031463
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY | |||
|
58083
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY | |||
|
17181-54-3
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY | |||
|
Glycerol 2-phosphate
Created by
admin on Fri Dec 15 15:38:16 GMT 2023 , Edited by admin on Fri Dec 15 15:38:16 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD